Skip to main content
OpenTrials
Completed

NCT Number: NCT03090360

Growth of Infants Fed a New Term Infant Formula

To evaluate the growth of healthy term infants fed an experimental infant formula with a prebiotic, a commercial control infant formula with a probiotic, but without a prebiotic and human breast milk

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

Up to 14 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Algemeen Stedelijk Ziekenhuis Aalst, Aalst, Belgium

Loading trial locations.

About this study

Multisite, double-blind, randomized, controlled clinical trial. The purpose of the study is to determine if infants fed a standard infant formula with a prebiotic have a weight gain in line with infants fed a standard starter infant formula without a prebiotic.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent signed and dated
  • Infants whose parent(s)/Legally Authorized Representative (LAR) have reached the legal age of majority in Belgium
  • Infants whose parent(s)/LAR are willing and able to comply with scheduled visits, and the requirements of the study protocol.
  • Infants whose parent(s)/LAR are able to be contacted directly by telephone throughout the study.
  • Infants whose parent(s)/LAR have a working freezer.
  • Healthy term, singleton infant at birth.
  • At enrollment visit, post-natal age ≤ 14 days (date of birth = day 0).
  • At enrollment, birth weight ≥ 2500g and ≤ 4500g.
  • For formula-fed group, infant of parent(s)/LAR who have previously made the decision to formula feed their infant at the time of enrollment.

Exclusion criteria

  • Infants with conditions requiring infant feedings other than those specified in the protocol.
  • Infants receiving complementary foods or liquids.
  • Infants who have a medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results.
  • Infants who are presently receiving or have received prior to enrollment medications that could interfere with the interpretation of study results.
  • Infants or infants whose parent(s)/LAR who in the Investigator's assessment cannot be expected to comply with the protocol or with study procedures.

Treatment and study plan

Infant formula (CF)

Dietary Supplement

Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.

Infant Formula (EF)

Dietary Supplement

Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.

Primary outcomes

  1. Growth

    Time frame: 120 days

    Growth (weight gain velocity)

Secondary outcomes

  1. Growth

    Time frame: Every month up to 6 months of age

    Other growth outcomes will be compared to the World Health Organization 2006 Growth Standards and by treatment group

  2. Stool patterns (3-day GI symptom and behavior diary - stool frequency and stool consistency)

    Time frame: Every month up to 6 months of age

    Stool patterns (3-day GI symptom and behavior diary - stool frequency and stool consistency)

  3. GI tolerance (3-day GI symptom and behavior diary - including GI symptoms, GI-related behaviors, and milk intake)

    Time frame: Every month up to 6 months of age

    GI tolerance (3-day GI symptom and behavior diary - including GI symptoms (frequency and amount of spitting-up/vomiting, and frequency of flatulence), GI-related behaviors (duration of crying and fussiness, sleeping, and the frequency of excessive crying episodes), and milk intake)

  4. Fecal microbiota composition and diversity (16S rRNA sequencing and qPCR)

    Time frame: Every month up to 4 months of age

    Fecal microbiota composition, diversity, and abundance

  5. Fecal markers (pH, fecal organic acids, and protein markers of gut health)

    Time frame: Every month up to 4 months of age

    Fecal markers (pH, fecal organic acids, and protein markers of gut health)

  6. Gene expression (infant exfoliated and microbial cell gene expression by shotgun sequencing)

    Time frame: Up to 3 months of age

    Gene expression (infant exfoliated and microbial cell gene expression by shotgun sequencing)

  7. Adverse events / Morbidity

    Time frame: 180 days

    Adverse events / Morbidity

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Official study title

Growth of Infants Fed a New Term Infant Formula With a Prebiotic

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Mar 24, 2017
Registry last updated
Jul 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.